Ming Dang1, Amy J Koh2, Theodora Danciu2, Laurie K McCauley2,3, Peter X Ma1,4,5. 1. Macromolecular Science and Engineering Center, University of Michigan, Ann Arbor, MI, 48109, USA. 2. Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, MI, 48109, USA. 3. Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA. 4. Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, 48109, USA. 5. Department of Materials Science and Engineering, The University of Michigan, Ann Arbor, MI, 48109, USA.
Abstract
Parathyroid hormone (PTH) is the only US Food and Drug Administration (FDA)-approved anabolic agent for the treatment of osteoporosis. The anabolic action of PTH depends on the mode of PTH administration. Pulsatile administration promotes bone formation, however continuous PTH exposure results in bone resorption. In addition, the therapeutic effect of PTH is optimal when the dose and duration fit the therapeutic window. Current PTH treatment requires daily injection, which is neither a convenient nor a favorable choice of patients. Here, an implantable and biodegradable device capable of long-term pulsatile delivery of PTH is developed as a patient-friendly alternative. The advanced materials and fabrication techniques developed in this work enable us to preprogram a pulsatile delivery device to systemically deliver 21 daily pulses of PTH that build bone in vivo. In addition, the device is biodegradable and absorbable in vivo so that no retraction procedure is needed. Therefore, this implantable and biodegradable pulsatile device holds promise to promote bone growth and treat various conditions of bone loss without the burden of daily injections or secondary surgeries.
Parathyroid hormone (pan class="Gene">PTH) is the only US Food and Drug Administration (FDA)-approved anabolic agent for the treatment of osteoporosis. The anabolic action of PTH depends on the mode of PTH administration. Pulsatile administration promotes bone formation, however continuous PTH exposure results in bone resorption. In addition, the therapeutic effect of PTH is optimal when the dose and duration fit the therapeutic window. Current PTH treatment requires daily injection, which is neither a convenient nor a favorable choice of patients. Here, an implantable and biodegradable device capable of long-term pulsatile delivery of PTH is developed as a patient-friendly alternative. The advanced materials and fabrication techniques developed in this work enable us to preprogram a pulsatile delivery device to systemically deliver 21 daily pulses of PTH that build bone in vivo. In addition, the device is biodegradable and absorbable in vivo so that no retraction procedure is needed. Therefore, this implantable and biodegradable pulsatile device holds promise to promote bone growth and treat various conditions of bone loss without the burden of daily injections or secondary surgeries.
Authors: Sun Wook Cho; Flavia Q Pirih; Amy J Koh; Megan Michalski; Matthew R Eber; Kathryn Ritchie; Benjamin Sinder; Seojin Oh; Saja A Al-Dujaili; JoonHo Lee; Ken Kozloff; Theodora Danciu; Thomas J Wronski; Laurie K McCauley Journal: J Biol Chem Date: 2013-01-07 Impact factor: 5.157
Authors: Brian P Timko; Manuel Arruebo; Sahadev A Shankarappa; J Brian McAlvin; Obiajulu S Okonkwo; Boaz Mizrahi; Cristina F Stefanescu; Leyre Gomez; Jia Zhu; Angela Zhu; Jesus Santamaria; Robert Langer; Daniel S Kohane Journal: Proc Natl Acad Sci U S A Date: 2014-01-13 Impact factor: 11.205
Authors: Glenda J Pettway; Jeffrey A Meganck; Amy J Koh; Evan T Keller; Steven A Goldstein; Laurie K McCauley Journal: Bone Date: 2007-12-15 Impact factor: 4.398
Authors: Amy C Richards Grayson; Insung S Choi; Betty M Tyler; Paul P Wang; Henry Brem; Michael J Cima; Robert Langer Journal: Nat Mater Date: 2003-11 Impact factor: 43.841